LevitasBio Launches LeviSelect Suite of Cell Depletion & Enrichment Kits
7.2.2023 15:53:00 EET | Business Wire | Press release
LevitasBio, Inc. (www.levitasbio.com), a premier end-to-end sample processing and cellular analysis provider to the life sciences market, unveils a suite of LeviSelect™ cell depletion and enrichment kits for immunology research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005645/en/
Five new LeviSelect Immune Cell Kits enable targeted enrichment of CD3 T Cells, CD4 T Cells, CD8 T Cells and Pan B Cells. Additional kits are also available under early access. (Graphic: Business Wire)
LeviSelect Kits are a targeted expansion of the revolutionary LeviCell™ Advanced Workflow fully integrated protocol that delivers an important new approach to cellular isolation and analysis, offering:
- Cells of interest are entirely label-free, unmodified or unperturbed with no gene expression or activation changes
- Live-cell enrichment, debris removal, and targeted selection all occur in a single simple step with no additional purifications, filtrations or consumables required
- Multiple LeviSelect kits can be multiplexed for a powerful and extremely targeted approach
For oncology or immuno-oncology research, LeviSelect CD45 Depletion Kits provide a highly effective method for the enrichment of pure tumor cells enabling characterization for drug discovery and biomarker identification.
LeviSelect Immune Kits support target selection of the immune subpopulations required for downstream cell analysis or further subsetting. Researchers can enrich hematopoietic populations quickly without lengthy workflows or potential cell activation.
- CD3 Enrichment
- CD4 Enrichment
- CD8 Enrichment
- Pan B Enrichment
- Pan Monocyte Enrichment
- NK Cell Enrichment
- Neutrophil Enrichment
Now T Cells, B Cells, NK Cell and Monocytes can be enriched simultaneously with viable cell enrichment in an untouched and unbiased manner. Future LeviSelect kits will include subtypes from these major populations.
“With the immediate launch of seven LeviSelect Kits—and six more available via our Early Access program—LevitasBio is enabling the streamline enrichment of these cells for downstream cell-based assays or immune profiling studies,” stated Martin Pieprzyk, CEO of LevitasBio. “This is highly impactful to catalyze novel discoveries in both academic and biopharma discovery research.”
Researchers, scientists, and labs who would like exclusive, priority access to future LeviSelect Kits can join the LevitasBio Early Access Program at https://levitasbio.com/early-access-program.
LevitasBio —True Biology Begins Here
Our mission is to advance science and human health by providing researchers with new and powerful methods of cellular analysis. LevitasBio delivers the first truly novel approach to cellular analysis in 30 years. Our proprietary label-free levitation technology enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, or modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005645/en/
Contact information
Steven Collier
Communication Liaison
steve@levitasbio.com
650-229-8596
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
rhode Launches at Sephora in Europe, Marking Its First Retail Presence Across 19 New Markets30.9.2026 09:30:00 EEST | Press release
rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), is available starting today, Wednesday, 30 September, 2026, at Sephora online and in over 500 stores across Europe. This expansion with Sephora in Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This follows the 2025 rollout with Sephora in the U.S., Canada, and the U.K. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929500812/en/ rhode launches into Sephora across Europe Launched in June 2022, rhode began with a curated lineup of efficacious skincare, expanding into hybrid makeup. Each launch has garnered tremendous demand, inspiring shifts across the beauty industry and culture at large. Today, rhode is the No. 1 overall skincare brand in the U.S. by EMV and continues to deliver significant year-over-year growth, according to CreatorIQ.* rhode is now available for con
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio ® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis30.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis.1 The findings will be shared in an oral presentation, titled ‘Long-term safety and efficacy (up to 152 weeks) of nemolizumab in ARCADIA open-label extension study in adults and adolescents with moderate-to-severe atopic dermatitis’, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, on Thursday, October 1, from 10:45-10:55 AM CET in Hall N by Dr. Matthias Augustin, an ARCADIA clinical trial investigator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929663019/en/ “These three-year data provide important evi
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill30.9.2026 08:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from threePhase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.1 Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026, these results demonstrate zasocitinib’s superior efficacy compared to deucravacitinib and reinforce the potential for zasocitinib to deliver rapid, durable and consistent skin clearance in a convenient once-daily pill.2-5 “Psoriasis is a heterogeneous disease driven by multiple immune pathways and TYK2 plays a central role in regulating several key inflammatory signals,” said Chinwe Ukomadu, M.D., Ph.D., Senior Vice President and Head, Gastrointestinal & Inflammation Therapeutic Area Unit at Takeda. “Across our Phase 3 trials, zasocitinib demonstrated superiority versus two distinct oral thera
Ant International’s Antom Supports Google Gemini in Expanding Access to AI Service in Asia30.9.2026 07:16:00 EEST | Press release
Google Gemini and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership to make AI tools for learning, creativity and productivity more accessible to users in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929520038/en/ Google AI Plus free trial offers are available in select digital payment and retail channels partnering with A+Rewards in Indonesia, with more markets to follow. Promoting Google AI Plus through AI-powered growth engine The collaboration will leverage A+Rewards, Antom’s digital marketing solution powered by privacy-preserving computing and AI technologies, and its extensive partner network of digital payment apps, e-commerce platforms and lifestyle service providers, to help expand access to Google AI Plus. Integrated into more than 30 leading digital platform partners, A+ Rewards provides in-app entry points where users
Signaloid Joins CERN openlab's Heterogeneous Architectures Testbed to Explore the Future of Scientific Computing30.9.2026 07:00:00 EEST | Press release
British computing company Signaloid has joined CERN openlab, the public-private partnership through which CERN evaluates emerging information technologies for scientific computing. As part of the collaboration, CERN and Signaloid will evaluate Signaloid's distribution-extended compute hardware (UxHw®) technology within the CERN openlab Heterogeneous Architectures Testbed, which explores new processor technologies for future scientific computing infrastructures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929985154/en/ Signaloid joins CERN openlab: Putting Signaloid's UxHw® Technology to the Test at the World's Largest Particle Collider The collaboration comes as research organisations worldwide are increasingly adopting heterogeneous computing architectures that combine CPUs, GPUs and specialised accelerators to tackle demanding workloads more efficiently. As the High-Luminosity Large Hadron Collider (HiLumi LHC) appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom